Catalyst
Slingshot members are tracking this event:
Following conclusion of Phase 2B study, BioPharmX Corporation (BPMX) to meet with FDA in mid-2017 before beginning Phase 3 trial of BPX-01, a drug treating acne vulgaris
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BPMX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 23, 2017
Occurred Source:
http://biopharmx.investorroom.com/2017-07-13-BioPharmX-To-Present-Phase-2b-Clinical-Trial-Data-at-National-DEF-Essential-Resource-Meeting-2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bpx-01, Acne Vulgaris, Fda Meeting
